C12N 2720/12261
Methods of inactivation or attenuation
C12N2720/12261 (Methods of inactivation or attenuation) appears on 11 US grants and 14 published applications in this corpus.
Search patents in C12N- Granted patents
- 11
- Published applications
- 14
- Assignees
- 10
- Inventors
- 15
- Latest grant
- 17 Aug 2021
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 1 | 1 |
| 2002 | 1 | 1 |
| 2003 | 1 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 1 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 3 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 2 |
| 2018 | 1 | 2 |
| 2019 | 1 | 1 |
| 2020 | 2 | 1 |
| 2021 | 1 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 1 |
By publication year. Applications have been published since 2001.
Subgroups
Granted patents
Recent patents
- Avian reovirus vaccines17 Aug 2021US 11,090,377 B2University of Georgia Research Foundation, Inc.
- Attenuated reovirus2 Jun 2020US 10,668,119 B2Virocure, Inc.
- Avian reovirus vaccines17 Mar 2020US 10,588,958 B2University of Georgia Research Foundations, Inc.
- Attenuated reovirus16 Apr 2019US 10,260,049 B2Virocure, Inc.
- Avian reovirus vaccines15 May 2018US 9,968,671 B2University of Georgia Research Foundation, Inc.
- Composition for preventing or treating inflammatory diseases of digestive system or colitis, comprising reovirus as active ingredient1 Jun 2023US 2023/0165916 A1Virocure, Inc.
- Avian reovirus vaccines5 Mar 2020US 2020/0069788 A1University of Georgia Research Foundation, Inc.
- Vaccines and Diagnostics for Novel Porcine Orthoreoviruses19 Dec 2019US 2019/0381165 A1Virginai Tech Intellectual Properties, Inc.
- Vaccines and diagnostics for novel porcine orthoreoviruses15 Nov 2018US 2018/0326034 A1Virginia Tech Intellectual Properties, Inc.
- Avian reovirus vaccines23 Aug 2018US 2018/0236061 A1University of Georgia Research Foundation, Inc.
Most cited
By later US patents
- Reovirus for the treatment of neoplasia46US 6,110,461 AOncolytics Biotech Inc. · 2000
- Reovirus for the treatment of neoplasia22US 6,261,555 B1Oncolytics Biotech Inc. · 2001
- Reovirus for the treatment of neoplasia20US 6,344,195 B12002
- Reovirus for the treatment of neoplasia9US 6,576,234 B2Oncolytics Biotech Inc. · 2003
- Reovirus for the treatment of neoplasia3US 7,300,650 B2Oncolytics Biotech Inc. · 2007